Authors
Latest:
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing PracticeRegistered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
How do PDX and Computational Models Assist in the Development of ADCs?Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
Latest:
Key Takeaways from the PARADIGM StudyDrs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Trevor J. Pugh, PhD, on Reducing the Burden of Serial Testing for MMRd With 1 Sequencing ProtocolCancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case ReportHans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Relapsed/Refractory CLL: Key Takeaways and Ongoing ChallengesClosing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
Latest:
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Latest:
Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALLClinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.
Latest:
CLL Workshop Emphasizes Engaging Conversations on Shared Treatment PlanningBoth clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Latest:
Key Takeaways From IMS Real-World Data on Managing Step-Up Dosing in Relapsed/Refractory Multiple MyelomaExperts discuss the growing evidence supporting outpatient administration of bispecific antibodies in multiple myeloma, emphasizing the need for multidisciplinary collaboration, patient education, and clear emergency protocols to safely expand this convenient, off-the-shelf treatment approach across disease stages, highlighting that partnerships with experienced centers and gradual implementation strategies are key to successful adoption and improved patient care.
Latest:
Unmet Needs and Future Perspectives in NSCLC TreatmentThe panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
